Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Veeva Soars in Market Debut on Demand for Cloud Software

Don't Miss Out —
Follow us on:

Oct. 16 (Bloomberg) -- Veeva Systems Inc., a maker of Web-based software for the medical industry, almost doubled in its stock market debut after twice raising the price of its initial public offering.

Veeva climbed 86 percent to $37.16 at the close in New York after earlier gaining as much as 98 percent. The company raised $260.9 million yesterday in the third-biggest U.S. technology IPO of the year, behind FireEye Inc. and Tableau Software Inc.

Investor demand for emerging business-software companies is surging as businesses shift from traditional server-based technology to products in the cloud. Veeva, based in Pleasanton, California, is going after medical companies looking to switch from Oracle Corp. and EMC Corp. products and sells to 33 of the 50 biggest pharmaceutical companies in the world, including Eli Lilly & Co. and Merck & Co.

“We are moving people from client/server into the cloud,” Chief Executive Officer Peter Gassner said today in an interview. “The legacy systems can’t keep up. They’re years and years behind.”

Veeva sold 13.05 million shares for $20 each yesterday. The company first set the price at $12 to $14 earlier this month and raised it to $16 to $18 before increasing it again.

Sales in the three months ended July 31 jumped 68 percent to $49.6 million, Veeva said in its prospectus. Unlike most newly public software companies, Veeva is profitable, recording net income of $6 million in the period.

With today’s gains, Veeva is valued at about $4.5 billion. The company’s biggest investor, Emergence Capital Partners, owns a 31 percent stake valued at about $1.3 billion.

Gassner co-founded the company after a two-year stint at Salesforce.com Inc. He quickly decided to target the pharmaceutical industry, betting that executives in this heavily regulated sector would pay a premium for software that’s compliant and simplifies documentation.

To contact the reporter on this story: Ari Levy in San Francisco at alevy5@bloomberg.net

To contact the editor responsible for this story: Pui-Wing Tam at ptam13@bloomberg.net